rss
Br J Ophthalmol 2006;90:819-822 doi:10.1136/bjo.2005.086850
  • Clinical science
    • Scientific reports

Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia

  1. J J Khong,
  2. J Muecke
  1. Department of Ophthalmology and Visual Science, Royal Adelaide Hospital, South Australia 5000, Australia
  1. Correspondence to: Dr James Muecke Department of Ophthalmology and Visual Science, Royal Adelaide Hospital, North Terrace, SA 5000, Australia; jsmuecke{at}bigpond.com
  • Accepted 9 March 2006
  • Published Online First 3 May 2006

Abstract

Aim: To determine the complications associated with mitomycin C (MMC) in the treatment of ocular surface neoplasia.

Methods: A retrospective and consecutive study of 100 eyes in 91 patients with ocular surface neoplasia treated with MMC in a single centre between November 1998 and January 2005. Outcome measures included complications of MMC and the treatment required for these complications.

Results: One to three 7 day cycles of topical MMC 0.04% four times a day were given to 59 eyes with localised corneal-conjunctival intraepithelial neoplasia (CIN), 19 eyes with diffuse CIN, six eyes with recurrent CIN, one eye with ocular surface squamous cell carcinoma, three eyes with primary acquired melanosis (PAM) with atypia, nine eyes with conjunctival malignant melanoma (MM), two eyes with sebaceous carcinoma with pagetoid spread, and one eye with recurrent atypical fibroxanthoma. Nine patients had bilateral CIN. 31 (34%) cases developed an allergic reaction to MMC and 14 (14%) eyes had epiphora secondary to punctal stenosis at a mean follow up period of 26.5 months.

Conclusion: In the largest study looking at complications of topical MMC in the treatment of ocular surface neoplasia, allergic reaction and punctal stenosis are relatively common. Serious complications were not observed suggesting the safe use of MMC in mid-term follow up.

Footnotes

  • Sponsors: none.

  • Competing interests: none.

  • Ethical approval: not required

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2005.086850v1
    2. 90/7/819 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.